Catalent, Inc. (NYSE:CTLT) Shares Acquired by ING Groep NV

ING Groep NV increased its stake in shares of Catalent, Inc. (NYSE:CTLT) by 162.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,130,504 shares of the company’s stock after buying an additional 699,851 shares during the quarter. ING Groep NV owned about 0.62% of Catalent worth $68,475,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in CTLT. Russell Investments Group Ltd. grew its stake in shares of Catalent by 14.9% in the first quarter. Russell Investments Group Ltd. now owns 27,636 shares of the company’s stock worth $1,560,000 after purchasing an additional 3,578 shares in the last quarter. ProShare Advisors LLC increased its stake in Catalent by 15.3% during the 1st quarter. ProShare Advisors LLC now owns 28,763 shares of the company’s stock valued at $1,624,000 after buying an additional 3,814 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in shares of Catalent by 2,792.9% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company’s stock worth $29,150,000 after buying an additional 498,540 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Catalent by 27.9% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 218,586 shares of the company’s stock worth $12,339,000 after acquiring an additional 47,739 shares during the period. Finally, Blair William & Co. IL boosted its holdings in shares of Catalent by 3.0% in the first quarter. Blair William & Co. IL now owns 41,998 shares of the company’s stock valued at $2,371,000 after acquiring an additional 1,220 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. StockNews.com raised Catalent from a “sell” rating to a “hold” rating in a report on Thursday. William Blair reissued a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Robert W. Baird reissued a “neutral” rating and set a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. Finally, Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Nine analysts have rated the stock with a hold rating, Based on data from MarketBeat, Catalent currently has an average rating of “Hold” and an average target price of $59.83.

Catalent Stock Up 0.3 %

Shares of CTLT traded up $0.16 during trading hours on Thursday, reaching $59.31. The company’s stock had a trading volume of 235,841 shares, compared to its average volume of 2,033,317. The company has a 50 day moving average of $59.89 and a two-hundred day moving average of $58.16. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The firm has a market cap of $10.77 billion, a price-to-earnings ratio of -26.17, a P/E/G ratio of 2.36 and a beta of 1.16. Catalent, Inc. has a 1-year low of $36.00 and a 1-year high of $61.20.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the prior year, the company posted ($0.10) EPS. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. As a group, research analysts predict that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Insider Buying and Selling at Catalent

In other Catalent news, insider David Mcerlane sold 1,994 shares of the stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.31% of the company’s stock.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.